Effects of clozapine, haloperidol and iloperidone on neurotransmission and synaptic plasticity in prefrontal cortex and their accumulation in brain tissue: An in vitro study

Neuroscience

Volumn 117, Issue 3, 2003, Pages 681-695

  Gemperle, A Y ^a,b   Enz, A ^a   Pozza, M F ^a   Luthi A ^b   Olpe, H R ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Antipsychotic drugs; LTP; NMDA receptor; Prelimbic cortex; Schizophrenia; Tissue concentration

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; CLOZAPINE; HALOPERIDOL; ILOPERIDONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; BRAIN SLICE; BRAIN TISSUE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFECT; DRUG MECHANISM; ELECTRIC POTENTIAL; ELECTRODE; EXCITATORY POSTSYNAPTIC POTENTIAL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; MASS SPECTROMETRY; MEMBRANE STEADY POTENTIAL; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; VOLTAGE CLAMP;

EID: 0037475154     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(02)00769-8     Document Type: Article

References (106)

1. Anderson W.W., Collingridge G.L. The LTP program a data acquistion program for on-line analysis of long-term potentiation and other synaptic events . J Neurosci Meth. 108:2001;71-83.
2. Aronidaou V.A., Keller A. The patterns and synaptic properties of horizontal intracortical connections in the rat motor cortex. J Neurophysiol. 70:1993;1553-1569.
3. Arvanov V.L., Liang X., Schwartz J., Grossman S., Wang R.Y. Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther. 283:1997;226-234.
4. Arvanov V.L., Wang R.Y. Clozapine, but not Haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine. J Pharmacol Exp Ther. 289:1999;1000-1006.
5. Baldessarini R.J., Centorrino F., Flood J.G., Volpicelli S.A., Houston-Lyons D., Cohen B.M. Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology. 9:1993;117-124.
6. Baldessarini R.J., Cohen B.M., Teicher M.H. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry. 45:1988;79-91.
7. Banerjee S.P., Zuck L.G., Yablonsky-Alter E., Lidsky T.I. Glutamate agonist activity implications for antipsychotic drug action and schizophrenia . Neuroreport. 6:1995;2500-2504.
8. Bear M.F., Press W.A., Connors B.W. Long-term potentiation in slices of kitten visual cortex and the effects of NMDA receptor blockade. J Neurophysiol. 67:1992;841-851.
9. Carlsson M., Carlsson A. Interaction between glutamatergic and monoaminergic systems within the basal ganglia implications for schizophrenia and Parkinson's disease . Trends Neurosci. 13:1990;272-276.
10. Cassens G., Inglis A.K., Applebaum P.S. Neuroleptics effects on neuropsychological function in chronic schizophrenic patients . Schizophrenia Bull. 16:1990;477-499.
11. Ceci A., Brambilla A., Duranti P., Grauert M., Grippa N., Borsini F. Effect of antipsychotic drugs and selective dopaminergic antagonists on dopamine-induced facilitatory activity in prelimbic cortical pyramidal neurons an in vitro study . Neuroscience. 93:1999;107-115.
12. Cleghorn J.M., Kaplan R.D., Szechtman H., Brown G.M. Neuroleptic drug effects on cognitive function in schizophrenia. Schizophr Res. 3:1990;211-219.
13. Cohen B.M., Tsuneizumi T., Baldessarini R.J., Campbell A., Babb S.M. Differences between antipsychotic drugs in persistence of brain levels and behavioral effects. Psychopharmacology. 108:1992;338-344.
14. Connors B.W., Gutnick M.J. Intrinsic firing patterns of diverse neocortical neurons. TINS. 13:1990;99-104.
15. Connors B.W., Gutnick M.J., Prince D.A. Electrophysiological properties of neocortical neurons in vitro. J Neurophysiol. 48:1982;1302-1320.
16. Corbett R., Camacho F., Woods A.T., Kerman L.L., Fishkin R.J., Brooks K., Dunn R.W. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviours. Psychopharmacology. 120:1995;67-74.
17. Cutmore T.R., Beninger R.J. Do neuroleptics impair learning in schizophrenic patients? Schizophr Res. 3:1990;173-186.
18. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia a review and reconceptualization . Am J Psychiatry. 148:1991;1474-1486.
19. Fletcher E.J., Church J., MacDonal J.F. Haloperidol blocks voltage-activated Ca2+ channels in hippocampal neruons. Eur J Pharmacol. 267:1994;249-252.
20. Fletcher E.J., Machado A. Haloperidol interacts with the strychnine-insensitive glycine site at the NMDA receptor in cultured mouse hippocampal neurones. Eur J Pharmacol. 235:1993;291-295.
21. Friedman J.I., Temporini H., Davis K.L. Pharmacological strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry. 45:1999;1-16.
22. Gellman R.L., Aghajanian G.K. Serotonin2 receptor-mediated excitation of interneurons in piriform cortex antagonism by atypical antipsychotic drugs . Neuroscience. 58:1994;515-525.
23. Hablitz J.J., Sutor B. Excitatory postsynaptic potentials in rat neocortical neurons in vitro. III. Effects of quinoxalinedione non-NMDA receptor antagonist. J Neurophysiol. 64:1990;1282-1290.
24. Hagger C., Buckley P., Kenny J.T., Friedmann L., Ubogy D., Meltzer H.Y. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry. 34:1993;702-712.
25. Haller E., Binder R.L. Clozapine-related seizures experience with 5,629 patients . Am J Psychiatry. 147:1990;1069-1071.
26. Hempel C.M., Hartman K.H., Wang X.-J., Turrigiano G.G., Nelson S.B. Multiple forms of short-term plasticity at excitatory synapses in rat medial prefrontal cortex. J Neurophysiol. 83:2000;3031-3041.
27. Hess G., Jacobs K.M., Donoghue J.P. N-methyl-D-aspartate receptor-mediated component of field potentials evoked in horizontal pathways of rat motor cortex. Neuroscience. 61:1994;225-235.
28. Hirota K., Kushikata T., Kudo M., Kudo T., Lambert D.G., Matsuki A. Orexin A and B evoke noradrenaline release from rat cerebrocortical slices. Br J Pharmacol. 134:2001;1461-1466.
29. Hirsch J.C., Crepel F. Use-dependent changes in synaptic efficacy in rat prefrontal neurons in vitro. J. Physiol. 427:1990;31-49.
30. Hirsch J.C., Crepel F. Blockade of NMDA receptors unmasks a long-term depression in synaptic efficacy in rat prefrontal neurons in vitro. Exp Brain Res. 85:1991;621-624.
31. Ichikawa J., Meltzer H.Y. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur Arch Psychiatry Clin Neurosci. 249:1999;90-98.
32. Jardemark K.E., Liang X., Arvanov V.L., Wang R.Y. Subchronic treatment with either clozapine, olanzapine or haloperidol produces a hyposensitive response of the rat cortical cells to N-methyl-D-asparate. Neuroscience. 100:2000;1-9.
33. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic a double-blind comparison with chlorpromazine . Arch Gen Psychiatry. 45:1988;789-796.
34. Kawaguchi Y. Grouping of nonpyramidal and pyramidal cells with specific physiological and morphological characteristics in rat frontal cortex. J Neurophysiol. 69:1993;416-431.
35. Keefe R.S.E., Silva S.G., Perkins D.O., Lieberman J.A. The effects of atypcial antipsychotic drugs on neurocognitive impairment in schizophrenia a review and meta-analysis . Schizophr Bull. 25:1999;201-222.
36. Kerkerian L.K., Dusticier N., Nieoullon A. Modulatory effect of dopamine on high-affinity glutamate uptake in the rat striatum. J Neurochem. 48:1987;1301-1306.
37. Kornhuber J., Schultz A., Wiltfang J., Meineke I., Gleiter C.H., Zoechling R., Boissl K.W., Leblhuber F., Riederer P. Persistence of haloperidol in human brain tissue. Am J Psychiatry. 156:1999;885-890.
38. Korpi E.R., Wong G., Lueddens H. Subtype specificity of gamma-aminobutyric acid type A receptor antagonism by clozapine. N-S Arch Pharmacol. 352:1995;365-373.
39. Kuroki T., Meltzer H.Y., Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther. 288:1999;774-781.
40. Langdon R.B., Sur M. Components of field potentials evoked by white matter stimulation in isolated slices of primary visual cortex spatial distributions and synaptic order . J Neurophysiol. 64:1990;1484-1501.
41. Laroche S., Davis S., Jay T.M. Plasticity at hippocampal to prefrontal cortex synapses dual roles in working memory and consolidation . Hippocampus. 10:2000;438-446.
42. Laroche S., Jay T.M., Thierry A.M. Long-term potentiation in the prefrontal cortex following stimulation of the hippocampal CA1/subicular region. Neurosci Lett. 114:1990;184-190.
43. Lavin A., Grace A.A. Dopamine modulates the responsivity of mediodorsal thalamic cells recorded in vitro. J. Neurosci. 18:2000;10566-10578.
44. Law-Tho D. Dopamine favours the emergence of long-term depression versus long-term potentiation in slices of rat prefrontal cortex. Neurosci Lett. 188:1995;125-128.
45. Law-Tho D., Hirsch J.C., Crepel F. Dopamine modulation of synaptic transmission in rat prefrontal cortex an in vitro electrophysiological study . Neurosci Res. 21:1994;151-160.
46. Lee M.A., Jayathilake K., Meltzer H.Y. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophr Res. 37:1999;1-11.
47. Leveque J.-C., Macias W., Rajadhyaksha A., Carlson R.R., Barczak A., Kang S., Li X.-M., Coyle J.T., Huganir L., Heckers S., Konradi C. Intracellular modulations of NMDA receptor function by antipsychotic drugs. J Neurosci. 20:2000;4011-4020.
48. Lewis D.A., Gonzalez-Burgos G. Intrinsic excitatory connections in the prefrontal cortex and the pathophysiology of schizophrenia. Brain Res Bull. 52:2000;309-317.
49. Lewis D.A., Lieberman J.A. Catching up in schizophrenia natural history and neurobiology . Neuron. 28:2000;325-334.
50. Lidsky T.I., Yablonsky-Alter E., Zuck L.G., Banerjee S.P. Anti-glutamatergic effects of clozapine. Neurosci Lett. 163:1993;155-158.
51. Lidsky T.I., Yablonsky-Alter E., Zuck L.G., Banerjee S.P. Antipsychotic drug effects on glutamatergic activity. Brain Res. 764:1997;46-52.
52. Malenka R.C. Postsynaptic factors control the duration of synaptic enhancement in area CA1 of the hippocampus. Neuron. 6:1991;53-60.
53. McCormick D.A., Connors B.W., Lighthall J.W., Prince D.A. Comparative electrophysiology of pyramidal and sparsely spiny stellate neurons of the neocortex. J Neurophysiol. 54:1985;782-806.
54. McCoy L., Richfield E.K. Chronic antipsychotic treatment alters glycine-stimulated NMDA receptor binding in rat brain. Neurosci Lett. 213:1996;137-141.
55. McGurk S.R. The effects of clozapine on cognitive functioning in schizophrenia. J Clin Psychiatry. 60:1999;24-29.
56. Medallia A., Gold J., Merriam A. The effects of neuroleptics on neuropsychological test results of schizophrenics. Arch Clin Neuropsychol. 3:1988;249-271.
57. Meltzer H., Nash J.F. Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev. 43:1991;587-604.
58. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull. 25:1999;233-255.
59. Michel F.J., Trudeau L.E. Clozapine inhibits synaptic transmission at GABAergic synapses established by ventral tegmental area neurones in culture. Neuropharmacology. 39:2000;1536-1543.
60. Miller E.K. The prefrontal cortex and cognitive control. Nat Rev Neurosci. 1:2000;59-65.
61. Mitchell V.A., Willow M., Nicholson G.M. Effects of antipsychotic agents on batrachotoxin-activated 22Na+ flux in rat brain synaptosomes. Clin Exp Pharmacol Physiol. 21:1992;49-52.
62. Moghaddam B., Bunney B.S. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat an in vivo microdialysis study . J Neurochem. 54:1990;1755-1760.
63. Mohn A.R., Gainetdinov R.R., Caron M.G., Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell. 98:1999;427-436.
64. Morris S.H., Knevett S., Lerner E.G., Bindman L.J. Group I mGluR agonist DHPG facilitates the induction of LTP in rat prelimbic cortex in vitro. J Neurophysiol. 82:1999;1927-1933.
65. Namba T., Morimoto K., Sato K., Yamada N., Kuroda S. Antiepileptogenic and anticonvulsant effects of NBQX, a selective AMPA receptor antagonist, in the rat kindling model of epilepsy. Brain Res. 638:1994;36-44.
66. Nicoll A., Larkman A., Blakemore C. EPSPs in rat neocortical pyramidal neurones in vitro are prolonged by NMDA receptor-mediated currents. Neurosci Lett. 143:1992;5-9.
67. Nowicky A.V., Bindman L.J. The nitric oxide synthase inhibitor, N-monomethyl-L-arginine blocks induction of a long-term potentiation-like phenomenon in rat medial frontal cortical neurons in vitro. J Neurophysiol. 70:1993;1255-1259.
68. Ohmori T., Koyama T., Yamashita I. Measurement of endogenous dopamine and norepinephrine release from superfused slices of rat prefrontal cortex in vitro modulation by D2 and alpha-2 presynaptic receptors . Life Sci. 48:1991;283-289.
69. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res. 33:1999;523-533.
70. Otmakhova N.A., Lisman J.E. Dopamine selectively inhibits the direct cortical pathway to the hippocampal region. J Neurosci. 19:1999;1437-1445.
71. Pacia S.V., Devinsky O. Clozapine and seizures. Neurology. 44:1994;2247-2249.
72. Pehek E.A., Yamamoto B.K. Differential effects of locally administered clozapine and haloperidol on dopamine efflux in the rat prefrontal cortex and caudate-putamen. J Neurochem. 63:1994;2118-2124.
73. Pencek T.L., Schauf C.L., Davis F.A. The effect of haloperidol on the ionic currents in the voltage-clamped node of Ranvier. J Pharmacol Exp Ther. 204:1978;400-405.
74. Penit-Soria J., Audinat E., Crepel F. Excitation of rat prefrontal cortical neurons by dopamine an in vitro electrophysiological study . Brain Res. 425:1987;263-274.
75. Richelson E., Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds . Life Sci. 68:2000;29-39.
76. Sawaguchi T., Goldman-Rakic P.S. D1 dopamine receptors in prefrontal cortex involvement in working memory . Science. 251:1991;947-950.
77. Schmutz M., Jeker A., Klebs K., Portet C.h, Pozza M., Fagg G.E., Heckendorn R., Allgeier H. CGP40116/CGP43487 competitive N-methyl-D-aspartate receptor antagonists with potent oral anticonvulsant activity . Epilepsia. 32:1991;59-60.
78. Seamans J.K., Durstewitz D., Christie B.R., Stevens C.F., Sejnowski T.J. Dopamine D1/D5 receptor modulation of excitatory synaptic inputs to layer V prefrontal cortex neurons. Proc Natl Acad Sci USA. 98:2000;301-306.
79. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse. 1:1987;133-152.
80. Sesack S.R., Deutch A.Y., Roth R.H., Bunney B.S. Topographical organization of the efferent projections of the medial prefrontal cortex in the rat an anterograde tract-tracing study with Phaseolus vulgaris leucoagglutinin . J Comp Neurol. 290:1989;213-242.
81. Sharma T. Cognitive effects of conventional and atypical antipsychotics in schizophrenia. Br J Psychiatry. 174:1999;44-51.
82. Sharma T. Effects of antipsychotic agents on cognitive function in schizophrenia. Curr Opinion CPNS Investigational Drugs. 2:2000;40-44.
83. Shi W.X., Zheng P., Liang X.F., Bunney B.S. Characterization of dopamine-induced depolarization of prefrontal cortical neurons. Synapse. 26:1997;415-422.
84. Shim S.S., Grant E.R., Singh S., Gallagher M.J., Lynch D.R. Actions of butyrophenones and other antipsychotic agents at NMDA receptors relationship with clinical effects and structural considerations . Neurochem Int. 34:1999;167-175.
85. Squires R.F., Saederup E. A review of evidence for GABAergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychoses more support for a continuum hypothesis of "functional" psychosis . Neurochem Res. 16:1991;1099-1111.
86. Squires R.F., Saederup E. Clozapine and several other antipsychotic/antidepressant drugs preferentially block the same "core" fraction of GABA(A) receptors. Neurochem Res. 23:1998;1283-1290.
87. A receptors. Neurochem Res. 22:1997;151-162.
88. 3 receptors. Neurochem Res. 24:1999;659-667.
89. Steckler T., Drinkenburg W.H., Sahgal A., Aggleton J.P. Recognition memory in rats. II. Neuroanatomical substrates. Prog Neurobiol. 54:1998;313-332.
90. Stip E. Memory impairment in schizophrenia perspectives from psychopathology and pharmacotherapy . Can J Psychiatry. 41:1996;27-34.
91. Sutor B., Hablitz J.J. EPSPs in rat neocortical neurons in vitro. II. Involvement of N-methyl-D-aspartate receptors in the generation of EPSPs. J Neurophysiol. 61:1989;621-634.
92. Tarazi F.I., Florijn W.J., Creese I. Chronic effects of typical and atypical neuroleptics on glutamate receptor subtypes. Schizophr Res. 15:1995;168-169.
93. Tarazi F.I., Florijn W.J., Creese O. Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology. 128:1996;371-379.
94. Tsuneizumi T., Babb S.M., Cohen B.M. Drug distribution between blood and brain as a determinant of antipsychotic drug effects. Biol Psychiatry. 32:1992;817-824.
95. +-dependent D-[3H]aspartate release from rat hippocampal slices. Neurochem Res. 20:1995;17-22.
96. Van Brederode J.F.M., Snyder G.L. A comparison of the electrophysiological properties of morphologically identified cells in layers 5B and 6 of the rat neocortex. Neuroscience. 50:1992;315-337.
97. Varela J.A., Sen K., Gibson J., Fost J., Abbott L.F., Nelson S.B. A quantitative description of short-term plasticity at excitatory synapses in layer 2/3 of rat primary visual cortex. J Neurosci. 17:1997;7926-7940.
98. Vickery R.M., Morris S.H., Bindman L.J. Metabotropic glutamate receptors are involved in long-term potentiation in isolated slices of rat medial frontal cortex. J Neurophysiol. 78:1997;3039-3046.
99. Wang J., O'Donnell P. D(1) dopamine receptors potentiate NMDA-mediated excitability increase in layer V prefrontal cortical pyramidal neurons. Cerebral Cortex. 11:2001;452-462.
100. 2A receptor antagonist and a potential atypical antipsychotic drug, facilitates induction of long-term potentiation in area CA1 of the rat hippocampal slice. Brain Res. 779:1998;309-313.
101. Wang R.Y., Liang M.D. M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice. Neuropsychopharmacology. 19:1998;74-85.
102. Weigmann H., Haertter S., Fischer V., Dahmen N., Hiemke C. Distribution of clozapine and desmethylclozapine between blood and brain in rats. Eur Neuropsychopharm. 9:1999;253-256.
103. Weinberger D.R., Aloia M.A., Goldberg T.E., Berman K.F. The frontal lobes and schizophrenia. J Neuropsychol Clin Neurosci. 6:1994;419-427.
104. Westlind-Danielsson A., Ericsson G., Sandell L., Elinder F., Arhem P. High concentrations of the neuroleptic remoxipride block voltage-activated Na+ channels in central and peripheral nerve membranes. Eur J Pharmacol. 224:1992;57-62.
105. Yang C., Seamans J.K., Gorelova N. Electrophysiological and morphological properties of layers V-VI principal pyramidal cells in rat prefrontal cortex in vitro. J Neurosci. 16:1996;1904-1921.
106. Zhang W., Pouzet B., Jongen-Relo A.L., Weiner I., Feldon J. Disruption of prepulse inhibition following N-methyl-D-aspartate infusion into the ventral hippocampus is antagonized by clozapine but not by haloperidol a possible model for the screening of atypical antipsychotics . Neuroreport. 10:1999;2533-2538.